Interleukin-35 as a predictor of prostate cancer in patients undergoing initial prostate biopsy
OncoTargets and Therapy Aug 12, 2017
Zhou C, et al. – The role of plasma interleukin (IL)–35 was contemplated here, in the diagnosis and prognosis of prostate cancer (PCa), among Chinese patients undergoing initial prostate biopsy. An association was brought to light between plasma IL–35 levels with PCa. It served as the independent predictor of PCa progression and metastasis. Therefore, IL–35 could be utilized as a potential biomarker for diagnosis and prognosis of PCa. It would also assist in decision making and would predict the stage of the disease.Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
55 lakhs+ doctors trust M3 globally
Unlimited access to original articles by experts
Secure: we never sell your data
Signing up takes less than 2 mins